X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46395) 46395
Newsletter (225) 225
Book Chapter (40) 40
Dissertation (40) 40
Magazine Article (32) 32
Publication (16) 16
Newspaper Article (12) 12
Conference Proceeding (6) 6
Web Resource (4) 4
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37252) 37252
female (26175) 26175
cisplatin - administration & dosage (25109) 25109
male (23135) 23135
cisplatin (21655) 21655
oncology (21580) 21580
middle aged (21144) 21144
antineoplastic combined chemotherapy protocols - therapeutic use (20910) 20910
aged (18132) 18132
adult (16727) 16727
chemotherapy (16549) 16549
cancer (12212) 12212
treatment outcome (8764) 8764
animals (7418) 7418
antineoplastic combined chemotherapy protocols - adverse effects (7407) 7407
combined modality therapy (7141) 7141
cisplatin - adverse effects (6342) 6342
lung neoplasms - drug therapy (6289) 6289
neoplasm staging (6170) 6170
fluorouracil - administration & dosage (5977) 5977
drug administration schedule (5417) 5417
survival rate (5055) 5055
antineoplastic agents - administration & dosage (5007) 5007
carcinoma (4684) 4684
antineoplastic combined chemotherapy protocols - administration & dosage (4665) 4665
prognosis (4624) 4624
doxorubicin - administration & dosage (4325) 4325
pharmacology & pharmacy (4234) 4234
care and treatment (4231) 4231
aged, 80 and over (4226) 4226
etoposide - administration & dosage (4152) 4152
carcinoma, non-small-cell lung - drug therapy (4023) 4023
cisplatin - therapeutic use (3966) 3966
radiotherapy (3942) 3942
therapy (3872) 3872
survival analysis (3866) 3866
retrospective studies (3837) 3837
disease-free survival (3810) 3810
mice (3773) 3773
paclitaxel (3675) 3675
survival (3621) 3621
carboplatin (3619) 3619
ovarian neoplasms - drug therapy (3585) 3585
paclitaxel - administration & dosage (3568) 3568
surgery (3544) 3544
carcinoma, squamous cell - drug therapy (3535) 3535
carboplatin - administration & dosage (3523) 3523
trial (3409) 3409
research (3344) 3344
follow-up studies (3294) 3294
antineoplastic agents - therapeutic use (3288) 3288
deoxycytidine - analogs & derivatives (3219) 3219
apoptosis (3215) 3215
chemotherapy, adjuvant (3099) 3099
lung neoplasms - pathology (3057) 3057
tumors (3018) 3018
dose-response relationship, drug (2976) 2976
medicine & public health (2955) 2955
deoxycytidine - administration & dosage (2883) 2883
cell line, tumor (2785) 2785
adenocarcinoma - drug therapy (2774) 2774
toxicity (2736) 2736
cisplatin - pharmacology (2726) 2726
cyclophosphamide - administration & dosage (2675) 2675
adolescent (2670) 2670
antineoplastic agents - adverse effects (2656) 2656
analysis (2606) 2606
gemcitabine (2563) 2563
vinblastine - administration & dosage (2530) 2530
stomach neoplasms - drug therapy (2522) 2522
combination (2436) 2436
rats (2426) 2426
time factors (2399) 2399
antineoplastic agents (2398) 2398
prospective studies (2303) 2303
doxorubicin (2264) 2264
bleomycin - administration & dosage (2205) 2205
metastasis (2194) 2194
ovarian cancer (2184) 2184
health aspects (2182) 2182
5-fluorouracil (2165) 2165
hematology, oncology and palliative medicine (2165) 2165
cancer therapies (2162) 2162
antimitotic agents (2125) 2125
phase-ii (2083) 2083
docetaxel (2080) 2080
remission induction (2061) 2061
drug therapy (2059) 2059
carcinoma, non-small-cell lung - pathology (2039) 2039
antineoplastic agents - pharmacology (2032) 2032
fluorouracil (2000) 2000
expression (1986) 1986
etoposide (1974) 1974
lung cancer (1970) 1970
methotrexate - administration & dosage (1940) 1940
carcinoma, squamous cell - pathology (1932) 1932
obstetrics & gynecology (1918) 1918
infusions, intravenous (1892) 1892
stomach neoplasms - pathology (1782) 1782
chemoradiotherapy (1776) 1776
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42533) 42533
Japanese (3801) 3801
French (568) 568
Chinese (524) 524
German (452) 452
Russian (194) 194
Italian (135) 135
Spanish (131) 131
Polish (79) 79
Hungarian (39) 39
Korean (37) 37
Portuguese (27) 27
Bulgarian (17) 17
Dutch (14) 14
Czech (12) 12
Ukrainian (12) 12
Persian (9) 9
Romanian (8) 8
Hebrew (7) 7
Turkish (6) 6
Lithuanian (5) 5
Serbian (5) 5
Slovak (4) 4
Danish (2) 2
Finnish (2) 2
Swedish (2) 2
Arabic (1) 1
Bosnian (1) 1
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop... 
Camptothecin | Stomach | Anthracyclines | Gastroenterology & hepatology | Cancer: other gastrointestinal | Palliation | Docetaxel | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Randomized Controlled Trials as Topic | Irinotecan | Chemotherapy | Treatment | Taxoids | Stomach Neoplasms | Medicine General & Introductory Medical Sciences | Fluorouracil | Cancer | 1ST-LINE TREATMENT | OLDER-ADULT PATIENTS | COLONY-STIMULATING FACTOR | Humans | Anthracyclines [administration & dosage] | Cisplatin [administration & dosage] | HIGH-DOSE 5-FLUOROURACIL | Fluorouracil [administration & dosage] | MEDICINE, GENERAL & INTERNAL | analogs & derivatives | RANDOMIZED PHASE-II | ADVANCED GASTROINTESTINAL CANCER | mortality | Taxoids [administration & dosage] | Antineoplastic Combined Chemotherapy Protocols [therapeutic use] | QUALITY-OF-LIFE | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Camptothecin [administration & dosage | Stomach Neoplasms [drug therapy | S-1 PLUS CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Stomach Neoplasms - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 2, pp. 523 - 535
Purpose: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small cell lung cancer (SCLC). Identification of predictors of response... 
BREAST-CANCER | TRIAL | INACTIVATION | ONCOLOGY | ABT-888 | PHASE-II | BRCA1 | DNA-REPAIR | DRUG RESPONSE | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | BMN 673 | Piperazines - administration & dosage | Dacarbazine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phthalazines - administration & dosage | Humans | Etoposide - administration & dosage | Small Cell Lung Carcinoma - genetics | Small Cell Lung Carcinoma - drug therapy | Indoles - administration & dosage | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Cisplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzimidazoles - administration & dosage | Dacarbazine - analogs & derivatives | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Genomics - methods | Nuclear Proteins - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Immunohistochemistry | CRISPR | Therapy | Effectiveness | Transcription | Small cell lung carcinoma | Lung cancer | Etoposide | Poly(ADP-ribose) polymerase | Immunoblotting | Single-nucleotide polymorphism | Gene expression | Cisplatin | Scars | Inhibitors | Experimental design | Correlation analysis | Xenografts | Biomarkers | In vivo methods and tests | Temozolomide | Combinatorial analysis | Cancer | SLFN11 | small cell lung cancer | biomarker | PARP inhibition | patient-derived xenografts
Journal Article